PANGEN BIOTECH INC.;SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
发明人:
Do Hyun NAM,Yong Jae SHIN,Jae Hyun LEE
申请号：
US15964763
公开号：
US20180245088A1
申请日:
2018.04.27
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention provides an antibody having cross-linking ability against human Sema3A and mouse Sema3A. The antibody of the present invention can be used as therapeutic antibody drugs for inhibiting Sema3A in various cancers in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as a therapeutic agent for associated diseases in addition to an anti-cancer drug. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas through inhibition of Sema3A function due to high anti-Sema3A binding, inhibits the movement of cancer cells through inhibition of phosphorylation of ERK among Sema3A lower signaling substances, it is very effective in the prevention and treatment of cancer.
